+44 (0)20 3910 4640 info@symmetron.net
  • 🗨 We’re hiring!
Symmetron
  • Services
  • Therapeutic areas
  • The Team
  • Careers
  • Contact
Select Page

Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK

by Symmetron | Jan 18, 2019

atrial fibrillation Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK Presented at ISPOR Europe.  November 10-14, 2018. Barcelona, Spain. Authors C. Rinciog, L....

Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...

Cost-Effectiveness of nintedanib in idiopathic pulmonary fibrosis in the U.S.

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y  Process \ Qualitative and...

A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A  Process \ An...

Recent Comments

    Archives

    Categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    © 2019 Symmetron Ltd